Aura Biosciences (AURA) News Today $6.40 -0.02 (-0.31%) Closing price 06/16/2025 04:00 PM EasternExtended Trading$6.40 0.00 (0.00%) As of 06/16/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of "Buy" from AnalystsAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has been given an average recommendation of "Buy" by the eight brokerages that are currently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and two have assigned a stroJune 1, 2025 | marketbeat.comResearch Analysts Issue Forecasts for AURA Q2 EarningsAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Investment analysts at HC Wainwright issued their Q2 2025 earnings estimates for Aura Biosciences in a research note issued on Wednesday, May 28th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($May 31, 2025 | marketbeat.comResearch Analysts Issue Forecasts for AURA FY2028 EarningsAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - HC Wainwright issued their FY2028 earnings per share (EPS) estimates for shares of Aura Biosciences in a research report issued on Wednesday, May 28th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per shareMay 30, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Aura Biosciences (NASDAQ:AURA)HC Wainwright reissued a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a research report on Wednesday.May 29, 2025 | marketbeat.comAura Biosciences (NASDAQ:AURA) Receives "Market Outperform" Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and issued a $19.00 price target on shares of Aura Biosciences in a report on Friday.May 25, 2025 | marketbeat.comJMP maintains $19 target on Aura Biosciences stock after FDA insightsMay 24, 2025 | uk.investing.comAura Biosciences, Inc. (NASDAQ:AURA) Director David Michael Johnson Acquires 20,000 SharesMay 21, 2025 | insidertrades.comEnsign Peak Advisors Inc Grows Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)Ensign Peak Advisors Inc grew its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 43.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 390,695 shares of the company's stock after purchasing an addMay 17, 2025 | marketbeat.comAura Biosciences Raises $69.9 Million in Public OfferingMay 16, 2025 | tipranks.comAura Biosciences Names Anthony Gibney Chief Financial, Business OfficerMay 16, 2025 | marketwatch.comDimensional Fund Advisors LP Buys 73,062 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)Dimensional Fund Advisors LP grew its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 25.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 365,824 shares of the company's stock after purchasingMay 16, 2025 | marketbeat.comAura Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comAura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comAura Biosciences Reports First Quarter 2025 Financial Results and Business HighlightsMay 15, 2025 | globenewswire.comAura Biosciences, Inc. (NASDAQ:AURA) Receives Average Rating of "Buy" from AnalystsAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has received an average rating of "Buy" from the eight analysts that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company.May 8, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Raises Stock Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)Price T Rowe Associates Inc. MD lifted its holdings in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 7.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 556,941 shares of the company's stock after purchasing an aMay 7, 2025 | marketbeat.comRenaissance Technologies LLC Has $688,000 Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)Renaissance Technologies LLC grew its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 489.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 83,700 shares of the company's stock afteMay 5, 2025 | marketbeat.comAura Biosciences (AURA) to Release Quarterly Earnings on ThursdayAura Biosciences (NASDAQ:AURA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-aura-biosciences-inc-stock/)May 3, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 37.3% in AprilAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 1,950,000 shares, an increase of 37.3% from the March 31st total of 1,420,000 shares. Based on an average trading volume of 256,400 shares, the short-interest ratio is presently 7.6 days. Approximately 4.4% of the shares of the company are sold short.May 3, 2025 | marketbeat.comAura Biosciences to Participate in Upcoming Investor ConferencesMay 1, 2025 | globenewswire.comAura Biosciences, Inc. (NASDAQ:AURA) Shares Bought by Long Focus Capital Management LLCLong Focus Capital Management LLC grew its position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 123.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,537,774 shares of the company's stApril 25, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Sees Large Increase in Short InterestAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 1,420,000 shares, an increase of 19.3% from the March 15th total of 1,190,000 shares. Approximately 3.2% of the shares of the stock are sold short. Based on an average daily volume of 250,000 shares, the days-to-cover ratio is presently 5.7 days.April 23, 2025 | marketbeat.comB Group Inc. Invests $3.89 Million in Aura Biosciences, Inc. (NASDAQ:AURA)B Group Inc. bought a new stake in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 472,576 shares of the company's stock, valued at approximately $3,885,000. Aura Biosciences accoApril 23, 2025 | marketbeat.comVanguard Group Inc. Acquires 112,296 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)Vanguard Group Inc. increased its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 6.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,917,730 shares of the company's stock after purchaApril 20, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Conor Kilroy Sells 7,162 SharesAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Conor Kilroy sold 7,162 shares of the business's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the sale, the insider now owns 179,313 shares in the company, valued at approximately $984,428.37. This trade represents a 3.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.April 18, 2025 | marketbeat.comEquities Analysts Offer Predictions for AURA Q1 EarningsAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Equities researchers at Leerink Partnrs cut their Q1 2025 earnings per share estimates for Aura Biosciences in a report issued on Tuesday, April 8th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.5April 13, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Receives Consensus Rating of "Buy" from AnalystsShares of Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) have been given a consensus recommendation of "Buy" by the eight brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and two have given a sApril 13, 2025 | marketbeat.comFranklin Resources Inc. Purchases 54,103 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)Franklin Resources Inc. lifted its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 3.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 1,723,063 shares of the company's stock after acquiring an additional 54,103 shares during theApril 9, 2025 | marketbeat.comIs Aura Biosciences (AURA) The Small Cap Stock with Huge Upside Potential?April 6, 2025 | msn.comAura Biosciences Announces Appointment of Teresa Bitetti to Board of DirectorsApril 2, 2025 | globenewswire.comBrokers Issue Forecasts for AURA Q1 EarningsAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for Aura Biosciences in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will post earnings per share of ($0.44) fMarch 28, 2025 | marketbeat.comAura Biosciences price target lowered to $19 from $21 at Citizens JMPMarch 27, 2025 | markets.businessinsider.comQ3 Earnings Forecast for AURA Issued By HC WainwrightAura Biosciences, Inc. (NASDAQ:AURA - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Aura Biosciences in a note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will posMarch 27, 2025 | marketbeat.comAura Biosciences (NASDAQ:AURA) Issues Quarterly Earnings ResultsAura Biosciences (NASDAQ:AURA - Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.09).March 26, 2025 | marketbeat.comAura Biosciences, Inc (AURA) Virtual Urologic Oncology Investor Event Call (Transcript)March 25, 2025 | seekingalpha.comHC Wainwright Reiterates Buy Rating for Aura Biosciences (NASDAQ:AURA)HC Wainwright restated a "buy" rating and issued a $22.00 price target on shares of Aura Biosciences in a report on Monday.March 25, 2025 | marketbeat.comAura Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Business HighlightsMarch 24, 2025 | globenewswire.comWith 48% stake, Aura Biosciences, Inc. (NASDAQ:AURA) seems to have captured institutional investors' interestMarch 24, 2025 | finance.yahoo.comPositive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology CongressMarch 24, 2025 | globenewswire.comAura Biosciences, Inc. (NASDAQ:AURA) Sees Significant Decline in Short InterestAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 1,120,000 shares, a drop of 13.2% from the February 13th total of 1,290,000 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average daily volume of 158,600 shares, the days-to-cover ratio is currently 7.1 days.March 20, 2025 | marketbeat.comAura Biosciences (AURA) to Release Quarterly Earnings on WednesdayAura Biosciences (NASDAQ:AURA) will be releasing earnings before the market opens on Wednesday, March 26, Financial Modeling Prep reports.March 19, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Given Average Recommendation of "Buy" by BrokeragesAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) has received an average recommendation of "Buy" from the seven ratings firms that are covering the stock, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to theMarch 17, 2025 | marketbeat.comAura Biosciences announces additional Phase 1 data on bel-sarMarch 4, 2025 | markets.businessinsider.comAura Biosciences Announces Additional Data from Ongoing Phase 1 Trial in Non-Muscle Invasive Bladder Cancer to be Presented as a Late-Breaking Abstract at the 40th Annual European Association of Urology CongressMarch 3, 2025 | globenewswire.comLevin Capital Strategies L.P. Boosts Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)Levin Capital Strategies L.P. lifted its position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 169.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,247,619 shares of the company's stock after buying an additionaMarch 2, 2025 | marketbeat.comAura Biosciences to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Aura Biosciences Inc (AURA), Springworks Therapeutics (SWTX)February 20, 2025 | markets.businessinsider.comAura Biosciences, Inc. (NASDAQ:AURA) SVP Sells $10,881.00 in StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) SVP Amy Elazzouzi sold 1,404 shares of the business's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total transaction of $10,881.00. Following the transaction, the senior vice president now directly owns 82,278 shares in the company, valued at approximately $637,654.50. The trade was a 1.68 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.February 19, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) CTO Sells $16,670.25 in StockAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) CTO Mark Plavsic sold 2,151 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $7.75, for a total value of $16,670.25. Following the completion of the sale, the chief technology officer now owns 209,456 shares in the company, valued at approximately $1,623,284. The trade was a 1.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.February 19, 2025 | marketbeat.comAura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 2,534 SharesAura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Janet Jill Hopkins sold 2,534 shares of Aura Biosciences stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $7.75, for a total transaction of $19,638.50. Following the completion of the sale, the insider now owns 269,794 shares of the company's stock, valued at approximately $2,090,903.50. The trade was a 0.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.February 19, 2025 | marketbeat.com Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address AURA Media Mentions By Week AURA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AURA News Sentiment▼1.870.90▲Average Medical News Sentiment AURA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AURA Articles This Week▼12▲AURA Articles Average Week Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amphastar Pharmaceuticals News Today Calliditas Therapeutics AB (publ) News Today Structure Therapeutics News Today Aurinia Pharmaceuticals News Today Wave Life Sciences News Today Niagen Bioscience News Today Mineralys Therapeutics News Today Arcus Biosciences News Today Spyre Therapeutics News Today Akebia Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AURA) was last updated on 6/17/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWill I be blacklisted?The President’s tour of the Middle East… the deal for Ukraine’s mineral rights… Elon’s strange time in Washing...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AURA Stock Free AURA Stock Alerts